At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BMEA Biomea Fusion, Inc.
Not Yet Opened 07-16 16:00:00 EDT
1.26
-0.03
-2.33%
盘后1.27
+0.01+0.79%
19:54 EDT
High1.27Low1.23Vol552.77K
Open1.27D1 Closing1.29Amplitude3.10%
Mkt Cap91.10MTradable Cap84.43MTotal Shares72.30M
T/O688.30KT/O Rate0.82%Tradable Shares67.01M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Biomea Fusion (BMEA) and Senseonics Holdings (SENS)
TIPRANKS  ·  06-24
Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Biomea Fusion (BMEA) and Senseonics Holdings (SENS)
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Novavax (NVAX)
TIPRANKS  ·  06-12
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and Novavax (NVAX)
Biomea Fusion shareholders elect two directors at annual meeting
Reuters  ·  06-11
Biomea Fusion shareholders elect two directors at annual meeting
Biomea Labs: Buy Rating Reiterated as Icovamenib Data Strengthen Metabolic Disease Thesis; $4 Price Target Maintained
TIPRANKS  ·  06-08
Biomea Labs: Buy Rating Reiterated as Icovamenib Data Strengthen Metabolic Disease Thesis; $4 Price Target Maintained
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“Ada”) 86TH Scientific Sessions and Announces Expansion of Ongoing Phase I Bmf-650 Study
THOMSON REUTERS  ·  06-06
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“Ada”) 86TH Scientific Sessions and Announces Expansion of Ongoing Phase I Bmf-650 Study
Biomea Fusion - Icovamenib Data Show Muscle Preservation and Fat Reduction in Obesity and Diabetes
THOMSON REUTERS  ·  06-06
Biomea Fusion - Icovamenib Data Show Muscle Preservation and Fat Reduction in Obesity and Diabetes
Biomea Fusion - Icovamenib Improves Hba1c and C-Peptide in Type 1 Diabetes With No Immune Activation
THOMSON REUTERS  ·  06-06
Biomea Fusion - Icovamenib Improves Hba1c and C-Peptide in Type 1 Diabetes With No Immune Activation
Biomea Fusion: Expanded Phase I Bmf-650 Study to Evaluate a Rapid One-Step Titration, Enhanced Weight Loss Potential With Oral Glp-1 Receptor Agonist
THOMSON REUTERS  ·  06-06
Biomea Fusion: Expanded Phase I Bmf-650 Study to Evaluate a Rapid One-Step Titration, Enhanced Weight Loss Potential With Oral Glp-1 Receptor Agonist
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
GlobeNewswire  ·  06-06
Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study
Biomea Fusion management to meet with Citizens
TIPRANKS  ·  06-05
Biomea Fusion management to meet with Citizens
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and IDEAYA Biosciences (IDYA)
TIPRANKS  ·  06-03
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA) and IDEAYA Biosciences (IDYA)
Biomea Fusion, University of Leicester to study icovamenib plus semaglutide in obesity trial
Reuters  ·  06-03
Biomea Fusion, University of Leicester to study icovamenib plus semaglutide in obesity trial
Biomea Fusion - Study to Evaluate Icovamenib With Semaglutide for Enhanced Weight Loss
THOMSON REUTERS  ·  06-03
Biomea Fusion - Study to Evaluate Icovamenib With Semaglutide for Enhanced Weight Loss
Biomea Fusion Announces Research Collaboration With University of Leicester to Evaluate Icovamenib in Combination With Semaglutide in Obesity
THOMSON REUTERS  ·  06-03
Biomea Fusion Announces Research Collaboration With University of Leicester to Evaluate Icovamenib in Combination With Semaglutide in Obesity
Oppenheimer Keeps Their Buy Rating on Biomea Fusion (BMEA)
TIPRANKS  ·  05-13
Oppenheimer Keeps Their Buy Rating on Biomea Fusion (BMEA)
Biomea Fusion to Participate at Upcoming Investor Conferences
GlobeNewswire  ·  05-13
Biomea Fusion to Participate at Upcoming Investor Conferences
Biomea Fusion Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-12
Biomea Fusion Inc reports results for the quarter ended March 31 - Earnings Summary
Biomea Fusion Q1 EPS $(0.17) Beats $(0.24) Estimate
Benzinga  ·  05-12
Biomea Fusion Q1 EPS $(0.17) Beats $(0.24) Estimate
Biomea Fusion Q1 net loss narrows as expenses fall
Reuters  ·  05-12
Biomea Fusion Q1 net loss narrows as expenses fall
Biomea Fusion Q1 FY26 net loss narrows to $12.4 million; cash falls to $45.1 million
Reuters  ·  05-12
Biomea Fusion Q1 FY26 net loss narrows to $12.4 million; cash falls to $45.1 million

Introduction

Company Name.
Biomea Fusion, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
Issue price:
--